{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-389785","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2026-09-14T10:20:15+00:00","discovered_at":"2026-09-14T10:25:01.637091+00:00","generated_at":"2026-09-14T10:25:28.725510+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Perspective Therapeutics and Merck collaborate on PSV359 + Keytruda for FAP-α solid tumors","bullets":["Clinical collaboration with Merck (NYSE: MRK) to evaluate [212Pb]PSV359 plus Keytruda in FAP-α positive solid tumors.","Amendment to ongoing Phase 1/2a study (NCT06710756) in NSCLC and colorectal cancer; first three monotherapy dose cohorts completed enrollment.","Merck supplies pembrolizumab at no cost; Perspective sponsors the study.","FAP-α expressed in majority of solid tumors; combination aims to reshape tumor microenvironment and improve outcomes."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-389785","json":"https://secwatch.observer/filing/0001193125-26-389785.json","markdown":"https://secwatch.observer/filing/0001193125-26-389785.md","text":"https://secwatch.observer/filing/0001193125-26-389785.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000119312526389785/0001193125-26-389785-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000119312526389785/catx-20260914.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-14T10:25:28.725510+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}